CARA Stock Price, Cara Therapeutics Inc Quote, Chart

Market Summary

USD0.69+0.03

Delayedas of 22 Apr 2024, 03:03 pm

4.55%

CARA Stock Price

View Fullscreen

CARA RSI Chart

CARA Valuation

Market Cap

36.1M

Price/Earnings (Trailing)

-0.3

Price/Sales (Trailing)

1.72

EV/EBITDA

0.4

Price/Free Cashflow

-0.38

CARA Price/Sales (Trailing)

CARA Profitability

EBT Margin

-402.70%

Return on Equity

-207.61%

Return on Assets

-94.17%

Free Cashflow Yield

-261.84%

CARA Fundamentals

CARA Revenue

Revenue (TTM)

21.0M

Rev. Growth (Yr)

-7.88%

Rev. Growth (Qtr)

-38.27%

CARA Earnings

Earnings (TTM)

-118.5M

Earnings Growth (Yr)

-6.59%

Earnings Growth (Qtr)

-15.36%

Breaking Down CARA Revenue

52 Week Range

0.654.67

(Low)(High)

Last 7 days

-13.2%

Last 30 days

-26.7%

Last 90 days

17.9%

Trailing 12 Months

-83.8%

How does CARA drawdown profile look like?

CARA Financial Health

Current Ratio

4.54

CARA Investor Care

Shares Dilution (1Y)

1.32%

Diluted EPS (TTM)

-2.19

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	43.2M	27.2M	21.2M	21.0M
2022	36.0M	48.9M	39.4M	41.9M
2021	107.1M	79.1M	51.0M	23.0M
2020	23.6M	24.0M	27.5M	135.1M
2019	17.9M	20.2M	20.9M	19.9M
2018	0	2.9M	7.9M	13.5M
2017	361.0K	636.0K	911.0K	911.0K
2016	0	2.6M	1.3M	86.0K
2015	3.5M	3.4M	4.7M	3.8M
2014	9.8M	7.6M	5.4M	3.2M
2013	0	4.8M	8.4M	12.0M
2012	0	0	0	1.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Cara Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 05, 2024	terrillion scott	sold	-2,284	0.83	-2,753	sec'y; chief compliance & g.c.
Apr 05, 2024	goncalves joana	sold	-2,284	0.83	-2,753	chief medical officer
Feb 29, 2024	terrillion scott	sold	-2,930	0.89	-3,293	sec'y; chief compliance & g.c.
Feb 29, 2024	posner christopher	sold	-5,192	0.89	-5,834	president and ceo
Feb 29, 2024	goncalves joana	sold	-2,930	0.89	-3,293	chief medical officer
Feb 08, 2024	posner christopher	sold	-18,854	0.53	-35,575	president and ceo
Feb 01, 2024	posner christopher	acquired	-	-	62,500	president and ceo
Feb 01, 2024	posner christopher	sold	-2,739	0.55	-4,981	president and ceo
Feb 01, 2024	menzaghi frederique ph.d.	acquired	-	-	13,500	chief scientific off,svp-r&d
Feb 01, 2024	terrillion scott	acquired	-	-	13,500	sec'y; chief compliance & g.c.

Which funds bought or sold CARA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 15, 2024	Sound Income Strategies, LLC	unchanged	-	17.00	91.00	-%
Apr 12, 2024	BALDWIN BROTHERS LLC/MA	unchanged	-	584	3,185	-%
Apr 11, 2024	DHJJ Financial Advisors, Ltd.	unchanged	-	-	2.00	-%
Apr 05, 2024	CWM, LLC	added	91.31	-	1,000	-%
Apr 03, 2024	Versant Capital Management, Inc	sold off	-100	-41.00	-	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	new	-	52.00	52.00	-%
Mar 15, 2024	B. Riley Wealth Advisors, Inc.	added	10.8	-47,677	45,812	-%
Mar 11, 2024	VANGUARD GROUP INC	added	1.26	-2,410,510	1,954,880	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	211	85,300	311,870	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.4	-21,942	17,273	-%

Are Funds Buying or Selling CARA?

Are funds buying CARA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CARA

No. of Funds

Unveiling Cara Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	bain capital life sciences opportunities iii, lp	0%	0	SC 13G/A
Feb 13, 2024	vanguard group inc	4.83%	2,631,067	SC 13G/A
Jan 29, 2024	blackrock inc.	6.5%	3,554,258	SC 13G/A
Jul 25, 2023	vifor (international) ltd	13.7%	7,396,770	SC 13G/A
Jul 07, 2023	blackrock inc.	6.9%	3,701,968	SC 13G/A
Feb 09, 2023	vanguard group inc	5.77%	3,101,724	SC 13G/A
Jan 26, 2023	blackrock inc.	14.4%	7,730,529	SC 13G/A
Jan 20, 2023	blackrock inc.	14.4%	7,730,529	SC 13G/A
Nov 18, 2022	bain capital life sciences opportunities iii, lp	5.0%	2,696,030	SC 13G
Feb 15, 2022	first manhattan co	0.0%	0	SC 13G/A

Recent SEC filings of Cara Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 12, 2024	PRE 14A	PRE 14A
Apr 09, 2024	4	Insider Trading
Apr 09, 2024	4	Insider Trading
Mar 22, 2024	8-K	Current Report
Mar 06, 2024	10-K	Annual Report
Mar 06, 2024	S-8	Employee Benefits Plan
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	8-K	Current Report

Peers (Alternatives to Cara Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	38.7B	6.8B	-1.66%	-28.18%	-8.22	5.66	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.2B	1.8B	-2.46%	-28.84%	-41.3	9.94	76.23%	61.08%
BMRN	16.7B	2.4B	4.57%	-8.46%	99.75	6.91	15.42%	18.43%
INCY	11.8B	3.7B	-10.11%	-29.11%	19.67	3.18	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-14.37%	-42.33%	-10.84	14.45	425.83%	18.94%
BBIO	4.4B	-	-13.59%	50.21%	-6.66	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-13.81%	-4.67%	-13.45	11.89	440.80%	-27.84%
ACAD	2.8B	726.4M	-9.91%	-15.82%	-45.22	3.82	40.45%	71.62%
ARWR	2.8B	240.7M	-20.67%	-25.33%	-9.32	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-10.64%	-8.42%	24.94	4.47	85.90%	-14.05%
NVAX	558.4M	983.7M	-17.39%	-51.52%	-1.02	0.57	-50.36%	17.16%
CRBP	409.4M	881.7K	-0.38%	387.14%	-9.18	466.16	-77.61%	-5.33%
INO	226.2M	4.9M	-10.29%	-2.81%	-1.67	46.49	-54.97%	51.71%
IBIO	6.0M	2.1M	59.81%	33.59%	-0.22	2.14	-13.45%	66.37%

Cara Therapeutics Inc News

Latest updates

Cara Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-38.3%	3,004,000	4,866,000	6,933,000	6,165,000	3,261,000	10,813,000	23,003,000	4,790,000	821,000	20,272,000	50,877,667	81,483,333	112,089,000	9,266,000	5,634,000	8,093,000	4,511,000	5,785,000	5,208,000	4,382,000	5,533,000
Operating Expenses	5.5%	35,611,000	33,764,000	39,273,000	33,815,000	34,568,000	34,658,000	27,475,000	32,701,000	34,343,000	21,396,000	30,876,000	25,496,000	33,799,000	26,286,000	31,518,000	38,094,000	34,481,000	40,218,000	29,350,000	27,516,000	27,510,000
S&GA Expenses	-2.5%	6,588,000	6,755,000	7,545,000	6,891,000	6,428,000	6,912,000	7,570,000	9,347,000	11,512,000	5,882,000	5,651,000	6,365,000	6,659,000	5,219,000	5,410,000	4,558,000	4,617,000	4,226,000	4,994,000	3,908,000	4,711,000
R&D Expenses	11.6%	28,415,000	25,451,000	30,310,000	24,334,000	26,010,000	24,691,000	19,905,000	21,273,000	22,831,000	15,514,000	25,225,000	19,131,000	27,140,000	21,067,000	26,108,000	33,536,000	29,864,000	35,992,000	24,356,000	23,608,000	22,799,000
EBITDA Margin	100.0%	-	-4.02	-3.14	-1.97	-2.04	-2.24	-1.80	-2.45	-3.83	0.47	0.10	0.13	0.06	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-255,000	-132,000	-182,000	-122,000	-166,000	-330,000	-235,000	-85,000	-125,000
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-33,382,000	-1,013,000	-30,745,000	-23,301,000	78,654,000	-16,641,000	-25,250,000	-29,044,000	-28,777,000	-33,172,000	-23,195,000	-22,045,000	-20,777,000
EBT Margin	100.0%	-	-4.03	-3.15	-1.98	-2.04	-2.24	-1.81	-2.46	-3.84	0.46	0.10	0.13	0.06	-	-	-	-	-	-	-	-
Net Income	-15.4%	-32,337,000	-28,032,000	-31,479,000	-26,665,000	-30,339,000	-23,180,000	-4,206,000	-27,749,000	-33,382,000	-1,013,000	-30,745,000	-23,301,000	78,909,000	-16,509,000	-25,068,000	-28,922,000	-28,611,000	-32,842,000	-22,960,000	-21,960,000	-20,652,000
Net Income Margin	-3.0%	-5.65	-5.49	-4.11	-1.95	-2.04	-2.25	-1.36	-2.58	-3.84	0.47	0.11	0.13	-	-	-	-	-	-	-	-	-
Free Cashflow	-Infinity%	-19,422,000	-	-20,445,000	-34,618,000	-23,510,000	-25,192,000	-4,503,000	-25,568,000	-1,412,000	-14,283,000	-21,172,000	-23,888,000	81,921,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	9.1%	126	115	134	153	182	214	227	224	247	225	221	250	271	147	169	196	233	264	150	171	191
Current Assets	15.5%	116	101	125	143	169	187	176	152	173	171	164	188	195	133	142	133	166	203	125	144	168
Cash Equivalents	-17.7%	52.00	63.00	58.00	47.00	64.00	43.00	47.00	22.00	14.00	23.00	23.00	23.00	32.00	76.00	57.00	17.00	19.00	35.00	19.00	15.00	16.00
Inventory	-13.6%	3.00	3.00	3.00	4.00	2.00	2.00	3.00	2.00	3.00	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	140.7%	3.00	1.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	-	69.00	-	-	-	23.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Current Liabilities	11.8%	26.00	23.00	25.00	17.00	23.00	28.00	21.00	18.00	18.00	16.00	15.00	17.00	18.00	17.00	25.00	33.00	43.00	48.00	40.00	42.00	40.00
Shareholder's Equity	-33.3%	57.00	86.00	109	137	159	185	204	204	228	207	203	230	249	128	141	160	187	212	100	115	134
Retained Earnings	-5.0%	-684	-652	-624	-592	-566	-535	-512	-508	-480	-447	-446	-415	-392	-471	-454	-429	-400	-372	-339	-316	-294
Additional Paid-In Capital	0.5%	742	738	734	731	727	723	719	714	709	699	650	646	641	599	595	590	587	584	439	431	428
Shares Outstanding	0.0%	54.00	54.00	54.00	54.00	54.00	54.00	54.00	54.00	51.00	50.00	50.00	50.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	131	-	-	-	417	-	-	-	696	-	-	-	726	-	-	-	784	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	11.6%	-17,370	-19,645	-20,445	-34,618	-23,510	-25,192	-4,503	-25,525	-1,245	-14,116	-21,005	-23,721	82,088	-21,620	-27,652	-38,303	-31,166	-25,637	-24,896	-27,526	-24,361
Share Based Compensation	8.0%	3,601	3,334	3,442	3,353	3,801	3,574	4,655	5,704	8,784	4,393	3,476	4,132	4,065	3,305	4,619	2,846	3,386	2,933	4,015	2,234	3,719
Cashflow From Investing	-230.4%	-30,205	23,155	32,803	17,708	44,423	21,176	29,677	33,431	-53,581	14,433	20,528	13,869	-164,155	39,539	67,382	36,959	14,738	-96,881	25,228	26,399	-57,831
Cashflow From Financing	3168.4%	36,475	1,116	-	560	22.00	104	182	3.00	45,288	339	293	688	38,469	395	201	75.00	28.00	138,368	3,974	234	544

CARA Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Total revenue	$ 20,968	$ 41,867	$ 23,028
Operating expenses:
Cost of goods sold	6,174	7,266
Research and development	108,510	91,879	82,701
General and administrative	27,779	30,257	29,410
Total operating expenses	142,463	129,402	112,111
Operating loss	(121,495)	(87,535)	(89,083)
Other income, net	3,586	2,061	642
Non-cash interest expense on liability related to sales of future royalties and milestones	(604)
Net loss	$ (118,513)	$ (85,474)	$ (88,441)
Net loss per share:
Basic	$ (2.19)	$ (1.59)	$ (1.74)
Diluted	$ (2.19)	$ (1.59)	$ (1.74)
Weighted average shares:
Basic	54,149,059	53,653,564	50,718,765
Diluted	54,149,059	53,653,564	50,718,765
Other comprehensive income (loss), net of tax of $0:
Change in unrealized gains (losses) on available-for-sale marketable securities	$ 1,412	$ (1,314)	$ (431)
Total comprehensive loss	(117,101)	(86,788)	(88,872)
Collaborative revenue
Revenue:
Total revenue	12,936	16,572	706
Commercial supply revenue
Revenue:
Total revenue	5,843	10,223	701
License and milestone fees
Revenue:
Total revenue	910	15,000	21,223
Royalty revenue
Revenue:
Total revenue	415	$ 72
Clinical compound revenue
Revenue:
Total revenue	165		$ 398
Other revenue
Revenue:
Total revenue	$ 699

CARA Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 51,775	$ 63,741
Marketable securities	48,983	81,658
Accounts receivable, net - related party	2,765	3,260
Inventory, net	2,821	2,383
Income tax receivable	697	697
Other receivables	555	496
Prepaid expenses	8,154	16,267
Restricted cash	408	408
Total current assets	116,158	168,910
Operating lease right-of-use assets	4,864	1,551
Marketable securities, non-current		11,350
Property and equipment, net	3,322	426
Restricted cash, non-current	1,500
Total assets	125,844	182,237
Current liabilities:
Accounts payable and accrued expenses	25,592	21,540
Operating lease liabilities, current		1,918
Total current liabilities	25,592	23,458
Liability related to sales of future royalties and milestones, net	37,079
Operating lease liabilities, non-current	6,088
Total liabilities	68,759	23,458
Commitments and contingencies (Note 19)
Stockholders' equity:
Preferred stock; $0.001 par value; 5,000,000 shares authorized at December 31, 2023 and December 31, 2022, zero shares issued and outstanding at December 31, 2023 and December 31, 2022
Common stock; $0.001 par value; 100,000,000 shares authorized at December 31, 2023 and December 31, 2022, 54,480,704 shares and 53,797,341 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	54	53
Additional paid-in capital	742,036	726,630
Accumulated deficit	(684,745)	(566,232)
Accumulated other comprehensive loss	(260)	(1,672)
Total stockholders' equity	57,085	158,779
Total liabilities and stockholders' equity	$ 125,844	$ 182,237

About Cara Therapeutics Inc

Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate, including Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. Cara Therapeutics, Inc. has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. and Winhealth Pharma for the co-development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis in China; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. The company was incorporated in 2004 and is based in Stamford, Connecticut.

CEO	Mr. Christopher A. Posner
WEBSITE	caratherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	106

Cara Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Cara Therapeutics Inc? What does CARA stand for in stocks?

CARA is the stock ticker symbol of Cara Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cara Therapeutics Inc (CARA)?

As of Fri Apr 19 2024, market cap of Cara Therapeutics Inc is 36.07 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CARA stock?

You can check CARA's fair value in chart for subscribers.

What is the fair value of CARA stock?

You can check CARA's fair value in chart for subscribers. The fair value of Cara Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cara Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CARA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cara Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether CARA is over valued or under valued. Whether Cara Therapeutics Inc is cheap or expensive depends on the assumptions which impact Cara Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CARA.

What is Cara Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, CARA's PE ratio (Price to Earnings) is -0.3 and Price to Sales (PS) ratio is 1.72. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CARA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Cara Therapeutics Inc's stock?

In the past 10 years, Cara Therapeutics Inc has provided -0.276 (multiply by 100 for percentage) rate of return.